Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease.
OBJECTIVE
To determine differences in clinical characteristics, laboratory findings, and cardiac complications between patients with acute Kawasaki disease who received additional treatment for persistent or recurrent fever vs those who did not.


METHODS
Nonconcurrent case series; medical record review.


METHODS
Tertiary care pediatric hospital.


METHODS
One hundred eighty-five consecutive patients diagnosed as having acute Kawasaki disease at The Hospital for Sick Children, Toronto, Ontario, from 1995 to 1997.


METHODS
Prevalence of cardiac complications.


RESULTS
Twenty-one patients (11%) received additional treatment with intravenous gamma globulin (IVGG) with or without intravenous methylprednisolone for persistent fever lasting for more than 48 hours or recurrent fever after initial treatment with IVGG. Patients who received additional treatment did not differ significantly from other patients regarding age, sex, race, or diagnostic criteria. Compared with the patients who did not receive additional therapy, the patients who received additional treatment had shorter median interval from fever onset to initial dose of IVGG (5 vs 6 days; P=.006) and longer total days of fever (9 vs 6 days; P<.001). Initial laboratory investigations did not differ significantly. On initial echocardiography, patients who received additional therapy were significantly more likely to have pericardial effusion (33% vs 15%; P=.04), ventricular dysfunction (14% vs 2%; P= .002), and coronary artery ectasia (76% vs 43%; P=.004) but not aneurysms (10% vs 5%; P= .47). At 12 months after diagnosis, there were no significant differences between the 2 groups regarding the prevalence of coronary artery ectasia or aneurysms.


CONCLUSIONS
Patients receiving additional treatment for persistent or recurrent fever have similar demographic and clinical characteristics, greater initial cardiac involvement, and similar overall outcomes.
Han
R K
RK
Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Ontario.
Silverman
E D
ED
Newman
A
A
McCrindle
B W
BW
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003323:Coronary Aneurysm / Q000175:diagnosis / Q000628:therapy; D005260:Female; D005334:Fever / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D007116:Immunization, Passive; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D009080:Mucocutaneous Lymph Node Syndrome / Q000175:diagnosis / Q000628:therapy*; D010043:Outcome and Process Assessment, Health Care; D012008:Recurrence; D019233:Retreatment
D000893:Anti-Inflammatory Agents; D008775:Methylprednisolone